Evidence map›Paper›PMID 38486989›Full record

ReviewActa pharmaceutica Sinica. B2024

The role of

Yu Lin, David M Lubman

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Acta pharmaceutica Sinica. B, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed, 1 pooled it
16.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 1 synthesis or guideline pooled it, 104 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Revealing the Biological Effect of theJournal of the American Chemical Society · 2026
    Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Yu LinDepartment of Surgery, University of Michigan Medical Center, Ann Arbor, MI 48109, USA.
David M LubmanDepartment of Surgery, University of Michigan Medical Center, Ann Arbor, MI 48109, USA.
University of Michigan–Ann Arbor · US

Funding

Supplemental for Detection of Glycopeptides of MCI in Patient SerumR01CA160254 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI David M. Lubman · 2012 to 2026
$5.4M
Screening of Glycan Markers in Serum for Early Detection of HCC in Different Etiologies of DiseaseU01CA225753 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LUBMAN, DAVID M., MECHREF, YEHIA · 2018 to 2021
$2.0M
NCI NIH HHS R01 CA160254NCI NIH HHS U01 CA225753
6 · The paper itself

Abstract

Despite advances in understanding the development and progression of cancer in recent years, there remains a lack of comprehensive characterization of the cancer glycoproteome. Glycoproteins play an important role in medicine and are involved in various human disease conditions including cancer. Glycan-moieties participate in fundamental cancer processes like cell signaling, invasion, angiogenesis, and metastasis. Aberrant

Indexed as

Cancer angiogenesisCancer biomarkersCancer metabolismCancer signalingN-Glycosylated proteins

Identifiers

PMID38486989
PMCPMC10935144
OpenAlexW4387953104

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.